Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MEDIROM Healthcare Technologies ( (MRM) ) just unveiled an update.
On October 21, 2025, MEDIROM Healthcare Technologies Inc. announced its interim financial results for the six months ended June 30, 2025. The report provides a detailed analysis of the company’s financial condition and operations, highlighting its strategic initiatives and market positioning. The release is significant for stakeholders as it reflects the company’s ongoing efforts to expand its HealthTech segment and maintain profitability amidst changing economic conditions and market dynamics.
The most recent analyst rating on (MRM) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
Spark’s Take on MRM Stock
According to Spark, TipRanks’ AI Analyst, MRM is a Neutral.
The overall stock score is driven primarily by strong technical analysis indicators, suggesting positive market momentum. However, financial performance concerns, particularly related to profitability and cash flow, weigh down the score. Valuation is reasonable, but the lack of a dividend yield is a minor drawback.
To see Spark’s full report on MRM stock, click here.
More about MEDIROM Healthcare Technologies
MEDIROM Healthcare Technologies Inc. is a leading holistic health services provider in Japan, operating 304 relaxation salons under the ‘Re.Ra.Ku®’ brand. Since 2015, the company has expanded into HealthTech, offering on-demand training apps and lifestyle improvement programs, and in 2020, it began manufacturing the battery-free smart tracker ‘MOTHER Bracelet®’, used in its remote monitoring system for various industries.
Average Trading Volume: 4,836,917
Technical Sentiment Signal: Hold
Current Market Cap: $19.2M
For detailed information about MRM stock, go to TipRanks’ Stock Analysis page.